CTI Collaborates With Vtesse on Novel Phase 2b/3 Clinical Trial for Treatment of Niemann-Pick Type C1 (NPC) Disease

“We’re thrilled to be partners with Vtesse and the entire NPC community in this effort to develop a drug that may be approved to treat this devastating disease,” according to Timothy J. Schroeder, CTI Chief Executive Officer. 

CTI Collaborated With Tuberous Sclerosis Alliance To Analyze Natural History Database

“We’re finding that groups like the Tuberous Sclerosis Alliance are becoming increasingly more important in drug development and research in rare diseases, as there is often a lack of information on rare disorders in published literature or traditional databases,” according to Joseph McCafferty, Vice President, North American Sales. 

CTI Broadens Use of Medidata Technology Platform for More Efficient, Higher Quality Clinical Trials

Medidata, the leading global provider of cloud-based solutions for clinical research in life sciences, today announced that CTI, a therapeutically-focused, full-service contract research organization, is expanding its use of the Medidata Clinical Cloud® platform to improve operational efficiencies, data accessibility and decision-making processes for its clinical trials.

80% of CTI Studies Meet or Exceed Enrollment Expectations

Most clinical trials fail to meet enrollment timelines, with more than 3/4 of trials delayed beyond initial projections. At CTI approximately 80% of our studies meet or exceed enrollment expectations, despite the challenging patient populations we work in, including rare diseases and gene therapy trials.

3 out of 4 Sites around the World Prefer CTI to Other CROs

CTI announced the results of the independently commissioned site survey that was sent out earlier this year. Overall, three out of four sites prefer CTI over all other CROs, and nearly 95% of respondents view CTI as equal to or better than other CROs that they have recently worked with.


Rare Disease / Orphan Disease

CTI is a leader in rare disease and orphan disease research with approximately 80% of our work falling into this category.

Learn More

Hematology / Oncology

CTI has unparalleled experience in working with complex and critically ill patients.

Learn More

Xavier University HECOR Degree Program

CTI's commitment to Health Outcomes is exemplified in our collaboration with Xavier University on a new Master’s program in Health Economic and Clinical Outcomes Research

Learn More

Participate in a Trial

Icon Careers Small Retina

CTI CRC is looking for volunteers to participate in our current trials. 

Learn More

Rare Disease Day 2016

Rare Disease Day 2016

For the third consecutive year, CTI is a proud partner of Rare Disease Day, taking place February 29th.

Learn More